Literature DB >> 29380923

Phacoemulsification outcomes in Boston terriers as compared to non-Boston terriers: a retrospective study (2002-2015).

Georgina M Newbold1, William J Kelch2, Thomas Chen1, Daniel A Ward1, Diane V H Hendrix1.   

Abstract

OBJECTIVES: To compare visual outcome and cause of blindness between two groups of dogs undergoing phacoemulsification. ANIMALS STUDIED: Study population consisted of 35 Boston terriers (BT; 70 eyes) and 77 non-Boston terriers (NBT; 154 eyes) that underwent bilateral phacoemulsification surgery. PROCEDURES: Medical records were reviewed to determine visual outcome, complications leading to blindness and follow-up. A Kaplan-Meier survival curve was used to estimate surgical success at 1 and 2 years postoperatively.
RESULTS: Eleven of 35 BT developed known vision loss, with 12 of 70 (17.1%) eyes becoming blind within one year of surgery, and 17 of 77 NBT developed known vision loss, with 19 of 154 (12.3%) eyes becoming blind within 1 year of surgery. No further vision loss was reported among those BT with a 2-year follow-up. In the NBT group, seven additional dogs, a total of 24 of 77 NBT developed vision loss, with a known total of 31 of 154 (20.1%) eyes becoming blind within two years of surgery. These results were not significantly different. The overall surgical success in both groups based on individual eyes was estimated to be between 80 and 90% at 1 year postsurgery and between 65 and 80% at 2 years postsurgery. Glaucoma was the leading cause of vision loss in both groups.
CONCLUSIONS: There was no significant difference in visual outcomes between a group of BT and a group of NBT undergoing bilateral phacoemulsification at the University of Tennessee between 2002 and 2015. Glaucoma was the leading cause of vision loss in both groups.
© 2018 American College of Veterinary Ophthalmologists.

Entities:  

Keywords:  Boston terrier; cataract; dogs; glaucoma; phacoemulsification

Mesh:

Year:  2018        PMID: 29380923     DOI: 10.1111/vop.12517

Source DB:  PubMed          Journal:  Vet Ophthalmol        ISSN: 1463-5216            Impact factor:   1.644


  6 in total

1.  Comparison of outcomes in cataractous eyes of dogs undergoing phacoemulsification versus eyes not undergoing surgery.

Authors:  Harathi Krishnan; Scott Hetzel; Gillian J McLellan; Ellison Bentley
Journal:  Vet Ophthalmol       Date:  2019-11-20       Impact factor: 1.644

2.  Phacoemulsification and intraocular lens implantation in a Canada lynx with phacoclastic uveitis.

Authors:  Geneviève Lavallée; Stephanie C Osinchuk; Dennilyn Parker; Marina Leis; Lynne S Sandmeyer
Journal:  Can Vet J       Date:  2022-03       Impact factor: 1.075

Review 3.  Looking into the future: Gene and cell therapies for glaucoma.

Authors:  András M Komáromy; Kristin L Koehl; Shin Ae Park
Journal:  Vet Ophthalmol       Date:  2021-01-07       Impact factor: 1.644

Review 4.  The future of canine glaucoma therapy.

Authors:  András M Komáromy; Dineli Bras; Douglas W Esson; Ronald L Fellman; Sinisa D Grozdanic; Larry Kagemann; Paul E Miller; Sayoko E Moroi; Caryn E Plummer; John S Sapienza; Eric S Storey; Leandro B Teixeira; Carol B Toris; Terah R Webb
Journal:  Vet Ophthalmol       Date:  2019-05-20       Impact factor: 1.644

5.  Outcome of phacoemulsification in 71 cats: A multicenter retrospective study (2006-2017).

Authors:  Elena Fenollosa-Romero; Emily Jeanes; Ines Freitas; Andra-Elena Enache; Rachel Lockhart; Lorraine Fleming; Timothy N L Knott; Charlotte Dawson; Kerry Smith; Claudia Busse
Journal:  Vet Ophthalmol       Date:  2019-07-22       Impact factor: 1.644

6.  Pro-inflammatory cytokines in aqueous humor from dogs with anterior uveitis and post-operative ocular hypertension following phacoemulsification, primary glaucoma, and normal healthy eyes.

Authors:  Hannah M Terhaar; Michala de Linde Henriksen; Lisa K Uhl; Corey Boeckling; Carolina Mehaffy; Ann Hess; Michael R Lappin
Journal:  PLoS One       Date:  2022-08-23       Impact factor: 3.752

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.